Skip to main content
OpenTrials
Completed

NCT Number: NCT02258542

A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA

The purpose of this study is to characterize the safety profile of benralizumab administration in asthma patients who have completed one of the three predecessor studies: D3250C00017, D3250C00018 or D3250C00020.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Asthma Bronchial Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

12 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Research Site, Buenos Aires, Argentina

Loading trial locations.

About this study

After a minimum of 1200 patients have been enrolled in this study, subsequent patients (up to a maximum of 2200 total for the study), who complete a minimum of 16 weeks, and no more than 40 weeks, in this study, will be given the option to transition to an open-label safety extension study, Study D3250C00037 (MELTEMI).

Adolescent patients, patients from Japan and South Korea, and any patient who chooses not to enter Study D3250C00037 will remain in this study through IPD or EOT and FU.

At the time of the first interim analysis in Japanese patients, the study regimen for all patients will become unblinded to AstraZeneca for data analysis purposes. Study conduct and blinding at the site and patient level will remain unchanged.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Informed consent (and/or assent as applicable locally) for study participation must be obtained prior to any study related procedures being performed (local regulations are to be followed in determining the assent/consent requirements for children and parent(s)/guardian(s)) and according to international guidelines and/or applicable European Union guidelines.
  • Female and male patients who completed the double-blind treatment period in a predecessor study on benralizumab or matching placebo.
  • Women of childbearing potential (WOCBP) must agree to use an effective form of birth control throughout the study duration and for 16 weeks after last dose of Investigational Product (IP).
  • For WOCBP only: Have a negative urine pregnancy test prior to administration of Investigational Product (IP) at Visit 1.
  • All male patients who are sexually active must agree to use a double barrier method of contraception (condom with spermicide) from the first dose of IP until 16 weeks after their last dose.

Exclusion criteria

  • Any disorder including but not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric or major physical impairment that is not stable in the opinion of the Investigator and could:
  • Affect the safety of the patient throughout the study
  • Influence the findings of the studies or their interpretations
  • Impede the patient's ability to complete the entire duration of study
  • A helminth parasitic infection diagnosed during a predecessor study that has either not been treated, has been incompletely treated or has failed to respond to standard of care therapy
  • Any clinically significant change in physical examination, vital signs, electrocardiogram (ECG), haematology, clinical chemistry, or urinalysis during a predecessor study which in the opinion of the investigator may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or interfere with the patient's ability to complete the entire duration of the study
  • Current malignancy or malignancy that developed during a predecessor study (subjects that had basal cell carcinoma, localized squamous cell carcinoma of the skin which was resected for cure, or in situ carcinoma of the cervix that has been treated/cured will not be excluded).
  • Receipt of live attenuated vaccines within 30 days prior to initiation of treatment in this study, during the treatment period, and for 16 weeks (5 half-lives) after the last dose of the investigational product
  • Receipt of immunoglobulin or blood products within 30 days prior to Visit 1
  • Planned major surgical procedures during the conduct of the study
  • Previous participation in the present study
  • Concurrent enrolment in another clinical trial
  • AstraZeneca staff involved in the planning and/or conduct of the study
  • Employees of the study centre or any other individuals involved with the conduct of the study or immediate family members of such individuals
  • Patients with major protocol deviations in any of the predecessor studies at the discretion of the Sponsor

Treatment and study plan

Benralizumab

Biological

Benralizumab administered subcutaneously

Primary outcomes

  1. Change From Baseline in Basophils, Full Analysis Set, Excluding MELTEMI Patients

    Time frame: Week 56

    Change from baseline in hematologic lab parameter of Basophils.

  2. Change From Baseline in Basophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)

    Time frame: Week 108

    Change from baseline in hematologic lab parameter of Basophils.

  3. Change From Baseline in Leukocytes, Full Analysis Set, Excluding MELTEMI Patients

    Time frame: Week 56

    Change from baseline in hematologic lab parameter of Leukocytes.

  4. Change From Baseline in Leukocytes, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)

    Time frame: Week 108

    Change from baseline in hematologic lab parameter of Leukocytes.

  5. Change From Baseline in Lymphocytes, Full Analysis Set, Excluding MELTEMI Patients

    Time frame: Week 56

    Change from baseline in hematologic lab parameter of Lymphocytes.

  6. Change From Baseline in Lymphocytes, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)

    Time frame: Week 108

    Change from baseline in hematologic lab parameter of Lymphocytes.

  7. Change From Baseline in Neutrophils, Full Analysis Set, Excluding MELTEMI Patients

    Time frame: Week 56

    Change from baseline in hematologic lab parameter of Neutrophils.

  8. Change From Baseline in Neutrophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)

    Time frame: Week 108

    Change from baseline in hematologic lab parameter of Neutrophils.

  9. Change From Baseline in Eosinophils, Full Analysis Set, Excluding MELTEMI Patients

    Time frame: Week 56

    Change from baseline in hematologic lab parameter of Eosinophils.

  10. Change From Baseline in Eosinophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)

    Time frame: Week 108

    Change from baseline in hematologic lab parameter of Eosinophils.

  11. Change From Baseline in Alanine Aminotransferase (ALT), Full Analysis Set, Excluding MELTEMI Patients

    Time frame: Week 56

    Change from baseline in chemistry tests ALT.

  12. Change From Baseline in ALT, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)

    Time frame: Week 108

    Change from baseline in hematologic lab parameter of ALT.

  13. Change From Baseline in Aspartate Aminotransferase (AST), Full Analysis Set, Excluding MELTEMI Patients

    Time frame: Week 56

    Change from baseline in chemistry tests AST.

  14. Change From Baseline in AST, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)

    Time frame: Week 108

    Change from baseline in hematologic lab parameter of AST.

  15. Change From Baseline in Bilirubin, Full Analysis Set, Excluding MELTEMI Patients

    Time frame: Week 56

    Change from baseline in chemistry test Bilirubin.

  16. Change From Baseline in Bilirubin, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)

    Time frame: Week 108

    Change from baseline in hematologic lab parameter of Bilirubin.

Secondary outcomes

  1. Number of Overall Patients With Asthma Exacerbations During Study Period

    Time frame: From week 0 to week 56 in study treatment period and through the follow up period (16 weeks from day of last dose)

    Annual asthma exacerbation rate, where an asthma exacerbation is defined by a worsening of asthma requiring the use of systemic corticosteroids for at least 3 days, and/or an in patient hospitalization, and/or an emergency department or urgent care visit

  2. Number of Overall Patients With Asthma Exacerbations During Study Period, Adolescents Only (SIROCCO/CALIMA)

    Time frame: From week 0 to week 108 in study treatment period and through the follow up period (16 weeks from day of last dose)

    Annual asthma exacerbation rate, where an asthma exacerbation is defined by a worsening of asthma requiring the use of systemic corticosteroids for at least 3 days, and/or an in patient hospitalization, and/or an emergency department or urgent care visit

  3. Change From Baseline in Pre-bronchodilator FEV1 (L)

    Time frame: Week 56

    Change from baseline to Week 56 in Pre-bronchodilator Forced expiratory volume in 1 second (FEV1).

  4. Change From Baseline in Pre-bronchodilator FEV1 (L), Adolescents Only (SIROCCO/CALIMA)

    Time frame: Week 108

    Change from baseline to Week 108 in Pre-bronchodilator Forced expiratory volume in 1 second (FEV1).

  5. Change From Baseline in Post-bronchodilator FEV1 (L)

    Time frame: Week 56

    Change from baseline to Week 56 in Post-bronchodilator Forced expiratory volume in 1 second (FEV1).

  6. Change From Baseline in Post-bronchodilator FEV1 (L), Adolescents Only (SIROCCO/CALIMA)

    Time frame: Week 108

    Change from baseline to Week 108 in Post-bronchodilator Forced expiratory volume in 1 second (FEV1).

  7. Change From Baseline in Asthma Control Questionnaire (ACQ) as a Measure of Asthma Control in Overall Patients

    Time frame: Week 56

    Asthma Control Questionnaire 6 (ACQ-6) contains 1 bronchodilator use question and 5 symptom questions. Questions were weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The mean ACQ-6 score was the mean of the responses.

  8. Change From Baseline in Asthma Control Questionnaire (ACQ) as a Measure of Asthma Control in Overall Patients, Adolescents Only (SIROCCO/CALIMA)

    Time frame: Week 108

    Asthma Control Questionnaire 6 (ACQ-6) contains 1 bronchodilator use question and 5 symptom questions. Questions were weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The mean ACQ-6 score was the mean of the responses.

  9. Change From Baseline in Total Score of Asthma Related and General Health-related Quality of Life Questionnaire (AQLQ(S)+12)

    Time frame: Week 56

    Standardised Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) comprises 4 separate domains (symptoms, activity limitations, emotional function, and environmental stimuli). It contains 32 questions on a 7 point scale ranging from 7 (no impairment) to 1 (severe impairment); total score is an average of all questions. An increase in score indicates improvement.

  10. Change From Baseline in Total Score of Asthma Related and General Health-related Quality of Life Questionnaire (AQLQ(S)+12), Adolescents Only (SIROCCO/CALIMA)

    Time frame: Week 108

    Standardised Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) comprises 4 separate domains (symptoms, activity limitations, emotional function, and environmental stimuli). It contains 32 questions on a 7 point scale ranging from 7 (no impairment) to 1 (severe impairment); total score is an average of all questions. An increase in score indicates improvement.

  11. Change of Blood Eosinophil Levels' Measurement in Overall Patients

    Time frame: Week 56

    Change from baseline to Week 56 in Blood eosinophils

  12. Change of Blood Eosinophil Levels' Measurement in Adolescents Patients (SIROCCO/CALIMA).

    Time frame: Week 108

    Change from baseline to Week 108 in Blood eosinophils.

  13. Change From Baseline in EQ-5D-5L Visual Analog Scale

    Time frame: Week 56

    The questionnaire included a visual analog scale (VAS) score, where the patient was asked to rate current health status on a scale of 0 to 100, with 0 being the worst imaginable health state; thus, an increase in VAS score indicated improvement.

  14. Change From Baseline in EQ-5D-5L Visual Analog Scale, Adolescents Only (SIROCCO/CALIMA)

    Time frame: Week 108

    The questionnaire included a VAS, where the patient was asked to rate current health status on a scale of 0 to 100, with 0 being the worst imaginable health state; thus, an increase in VAS score indicated improvement.

  15. Work Productivity Loss in Adults, Using Work Productivity and Activity Impairment Questionnaire (WPAI)

    Time frame: Week 68

    The WPAI+CIQ is a 10-item questionnaire that assesses productivity and activity impairment over the previous week. The questionnaire includes hours missed from work/school due to asthma, degree health affected productivity while at work/school, as well as the degree to which health affected regular activities other than work or school. The questionnaire related to the previous 7 days. Work productivity loss is calculated with sum of hours missed at work due to health problem and hours that affected due to health problem at work, divided by sum of hours missed due to health problem and hours actually worked, presented by percentage.

  16. Work Productivity Loss in Adults, Using Work Productivity and Activity Impairment Questionnaire (WPAI), Adolescents Only (SIROCCO/CALIMA)

    Time frame: Week 108

    The WPAI+CIQ is a 10-item questionnaire that assesses productivity and activity impairment over the previous week. The questionnaire includes hours missed from work/school due to asthma, degree health affected productivity while at work/school, as well as the degree to which health affected regular activities other than work or school. The questionnaire related to the previous 7 days. Work productivity loss is calculated with sum of hours missed at work due to health problem and hours that affected due to health problem at work, divided by sum of hours missed due to health problem and hours actually worked, presented by percentage.

  17. Classroom Productivity Loss Using Classroom Impairment Questionnaire (CIQ)

    Time frame: Week 56

    The WPAI (+CIQ) is a 10-item questionnaire that assesses productivity and activity impairment over the previous week. The questionnaire includes hours missed from work/school due to asthma, degree health affected productivity while at work/school, as well as the degree to which health affected regular activities other than work or school. The questionnaire related to the previous 7 days. Classroom productivity loss is calculated with sum of hours missed for classes due to health problem and hours that affected due to health problem in classes, divided by sum of hours missed due to health problem and hours actually attended classes, presented by percentage.

  18. Classroom Productivity Loss Using Classroom Impairment Questionnaire (CIQ), Adolescents Only (SIROCCO/CALIMA)

    Time frame: Week 108

    The WPAI (+CIQ) is a 10-item questionnaire that assesses productivity and activity impairment over the previous week. The questionnaire includes hours missed from work/school due to asthma, degree health affected productivity while at work/school, as well as the degree to which health affected regular activities other than work or school. The questionnaire related to the previous 7 days. Classroom productivity loss is calculated with sum of hours missed for classes due to health problem and hours that affected due to health problem in classes, divided by sum of hours missed due to health problem and hours actually attended classes, presented by percentage.

  19. Activity Impairment (%), Using Work Productivity and Activity Impairment Questionnaire (WPAI)

    Time frame: Week 68

    The WPAI+CIQ is a 10-item questionnaire that assesses productivity and activity impairment over the previous week. The questionnaire includes hours missed from work/school due to asthma, degree health affected productivity while at work/school, as well as the degree to which health affected regular activities other than work or school. The questionnaire related to the previous 7 days. The WPAI+CIQ outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.

  20. Activity Impairment (%), Using Work Productivity and Activity Impairment Questionnaire (WPAI), Adolescents Only (SIROCCO/CALIMA)

    Time frame: Week 108

    The WPAI+CIQ is a 10-item questionnaire that assesses productivity and activity impairment over the previous week. The questionnaire includes hours missed from work/school due to asthma, degree health affected productivity while at work/school, as well as the degree to which health affected regular activities other than work or school. The questionnaire related to the previous 7 days. The WPAI+CIQ outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.

  21. Number of Patients Who Had Health Care Encounter (ie, Hospitalization, Emergency Department Visits, Urgent Care Visits, and All Other Outpatient Visits Due to Asthma) During Study Period

    Time frame: From week 0 to week 68 in study treatment period and through the follow up period (16 weeks from day of last dose)

    Hospitalizations, Emergency department (ED) visits, urgent care visits and all other outpatient visits due to asthma

  22. Number of Patients Who Had Health Care Encounter (ie, Hospitalization, Emergency Department Visits, Urgent Care Visits, and All Other Outpatient Visits Due to Asthma) During Study Period, Adolescents Only (SIROCCO/CALIMA)

    Time frame: Baseline and Week 108

    Hospitalizations, ED visits, urgent care visits and all other outpatient visits due to asthma

  23. Pre-dose Benralizumab Concentration in Serum During the Treatment Phase of the Safety Study

    Time frame: Week 0 and Week 56

    Endpoint: Pharmacokinetic (PK) parameters

  24. Pre-dose Benralizumab Concentration in Serum During the Treatment Phase of the Safety Study, Adolescents Only (SIROCCO/CALIMA)

    Time frame: Baseline and Week 108

    Endpoint: Pharmacokinetic (PK) parameters

  25. Number of Patients With Anti-drug Antibodies (ADA) Responses During the Study

    Time frame: From week 0 to week 56 in study treatment period (adults) and plus 16 weeks the follow up period; From week 0 to week 108-week in study treatment period (adolescents) and plus 16 weeks the follow up period

    Assessments for the presence of ADA and neutralizing antibody (nAb) throughout study

  26. Number of Patients With Anti-drug Antibodies (ADA) Responses During the Study, Adolescents Only (SIROCCO/CALIMA)

    Time frame: From week 0 to week 108 study treatment period (adults) and plus 16 weeks the follow up period; From week 0 to week 108-week in study treatment period (adolescents) and plus 16 weeks the follow up period

    Assessments for the presence of ADA and nAb throughout study

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

A Multicentre, Double-blind, Randomized, Parallel Group, Phase 3 Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus Long-acting β2 Agonist (BORA)

Acronym: BORA

Important dates

Study start
2014
Primary completion
2017
Study completion
2018
First posted
Oct 7, 2014
Registry last updated
Aug 21, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.